Astellas antibiotic new product Dafclir has been approved in Japan for the treatment of infectious enteritis

CD is a bacteria that infects the large intestine and produces toxins that cause hospital infections and antibiotic-related colitis worldwide
CD infections and proliferation can lead to colitis and severe diarrhea, and in the most severe cases can lead to deathThedrugcurrently on the market (difficulties in treating CD-induced infectious enteritis, mainly due to relapse, there is an urgent need for new treatment options in this area)recently announced that the newproduct(fidaxomicin, non-damycin) has been approved in Japan to treat infectious enteritis (including pseudo-membrane colitis (PMC), the Japanese pharmaceutical company Astellas announcedabout Dafclir
Dafclir is an oral, large-ring ester antibiotic with a new mechanism of action and a selective antibacterial spectrum, which is mainly by inhibiting the bacteria's RNA polymerase to produce rapid anti-treatment clostridium dyspore infection (CDI) effectDafclir was acquired by Astellas under the authority of Merck and Co, which is responsible for the development of the product in the Japanese marketin addition to, Astellas Europe's sub-
company(also obtained exclusive license for the development and commercialization of the product in Europe, the Middle East, Africa, CIS)In Europe, Dafclir is on the market for the treatment of CD infections